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Electrical and Gene Therapies for Wound Healing
Exogenous growth factors have been successfully used to
accelerate wound healing in humans and animal models.
A less expensive alternative, however, is to administer a
gene that encodes growth factor. Transforming growth
factor (TGF)-b1 is a chemokine for fibroblasts that
enhances granulation tissue but is a potent inhibitor of
keratinocyte proliferation in vitro. Electroporation is also a
cell-migration promoter and can enhance cell permeability
to allow DNA penetration. The combination of electric pulses and delivery of TGF-b1
plasmid provided an innovative synergism to treat diabetic wound healing in the db/
db (diabetic) mouse. The findings by Lee and co-workers may have a significant
implication for clinical applications. J Invest Dermatol 123:791–798, 2004.
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Women Are Catching Up
In the Netherlands, basal cell cancer (BCC) is the most common
malignant tumor in pale-skinned individuals. Where a ‘‘typical’’ BCC patient
has traditionally been an older male with chronic sun exposure usually on the
head and neck, data now show young or middle-aged females who sunbathe in
shorter, more intense bursts are increasingly presenting with tumors on the trunk and
limbs. When de Vries and coworkers considered hypotheses for this change in the
20th century, they identified increasing leisure time, different cultural mores and
patterns of clothes and body exposure, and more affordable travel costs to tropical
destinations. J Invest Dermatol 123:634–638, 2004.
SCC in RDEB
Recessive dystrophic epidermolysis
bullosa (RDEB) is an autosomal
recessive disorder characterized by
mutations of collagen type VII.
Although RDEB leads to numerous
serious morbidities, the major cause
of death is cutaneous squamous cell
carcinoma (SCC) related to the
atrophic scars. Arbiser and collea-
gues, analyzing eight RDEB tumors,
identified specific abnormalities in
both the p53 and p16ink4a tumor
suppressor genes and conclude that
these pathways are involved in the
pathogenesis of this severe form of
SCC. Future animal studies may
increase our understanding of the
molecular mechanisms driving the
carcinogenesis and may lead to
urgently needed chemopreventive
and treatment strategies, both for
RDEB patients and others. J Invest
Dermatol 123:788–790, 2004.
Tea Tames Weal and Flare
Determining the bioactive mechanisms of essential oils is not an easy
task. Tea tree oil (TTO), from the Australian plantMelaleuca alternifolia,
reduces histamine-induced vascular responses in humans. Khalil and
colleagues dissected TTO’s effect on inflammatory microvascular
changes of rat blisters to identify the active components and the
mechanism of action. After histamine injection in human skin, terpinen-
4-ol (40% TTO), but not a-terpineol or 1,8-cineole (3% and 2% TTO,
respectively), downregulated the developing weal and flare. The
rodent and human studies complement the analysis of the mode of
action of immunoregulatory preparations on skin inflammation.
J Invest Dermatol 123:683–690, 2004.
(Photo Tea trees (Melaleuca alternifolia) growing at Australian Plantations in Wyrallah, New
South Wales, Australia. Courtesy of University of Western Australia.)
Angiogenesis and Wound Healing
While healing, cutaneous wounds have many new capillaries and granulation tissue.
Eming and colleagues looked at angiogenesis impairment in patients with normal-
healing acute and non-healing chronic wounds. Vascular endothelial growth factor
(VEGF)-A is pivotal in the angiogenic response. sVEGFR-1 inhibits VEGF-A and,
consequently, angiogenesis. Inducing sVEGFR-1 expression to non-physiologic
levels will promote understanding of which factor in wound fluid is responsible for
such an induction. Detection of sVEGFR-1 may lead to better assessment of disease
severity and progression, and may serve as an indicator of therapeutic efficacy of
topical and systemic therapy. J Invest Dermatol 123:799–802, 2004.
The Mystery of
Mutating Moles
Many benign and malignant melano-
cytic lesions exhibit BRAF gene
mutations, usually as V599E (chan-
ging valine at protein 599 to glutamic
acid). Loewe and colleagues exam-
ined 324 lesions that were unre-
markable at initial visit but showed
structure and/or size changes at
follow-up. Photo-documentation and
then excision showed 24 of them to
be melanomas. The BRAFV599E mu-
tation correlated with sudden onset
of lesion growth. Even though histol-
ogy proved that many samples were
benign, nevi with BRAF mutations
may still be melanocytic. Since
BRAF mutations cause cell prolifera-
tion in vivo, Sherlock Holmes will
need to take the case of proliferating
pigmented papules and macules. J
Invest Dermatol 123:733–736, 2004.
1 mm 
Copyright r 2004 by The Society for Investigative Dermatology, Inc.
vi
